Pleural Fluid Cytology Detects Small Cell Carcinoma Transformation in EGFR-Mutant Lung Adenocarcinoma: A Case Report
Huijun Zhou1, Zhengyue He2, Zhuo Wang3
1Department of Laboratory Medicine, Suining Central Hospital, Suining, Sichuan Province, China.
Background:
Histological transformation of lung adenocarcinoma to small cell carcinoma is a rare but critical mechanism of acquired resistance to EGFR-TKIs.
Case:
A 65-year-old woman with EGFR-mutant lung adenocarcinoma developed new-onset massive pleural effusion after an initial partial response to icotinib. Pleural fluid cytology revealed tumor cells with high nuclear-to-cytoplasmic ratio, finely granular chromatin, and nuclear molding, features suggestive of small cell carcinoma. Cell block immunohistochemistry confirmed small cell carcinoma (CD56+, Syn+, TTF-1+). Molecular testing demonstrated persistence of the original EGFR exon 19 deletion mutation, and single-cell sequencing supported clonal origin.
Conclusion:
Integrated cytological and molecular analysis of pleural fluid can provide compelling evidence supporting small cell transformation in EGFR-mutant lung adenocarcinoma. The shared EGFR mutation between the primary and transformed tumors is consistent with clonal evolution. This minimally invasive approach offers a practical alternative to tissue re-biopsy for monitoring acquired resistance to EGFR-TKIs.
Insights
Histological transformation to small cell carcinoma is a resistance mechanism in EGFR-mutant lung adenocarcinoma. Analyzing pleural fluid offers a minimally invasive way to detect this transformation and monitor treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Histological transformation of lung adenocarcinoma to small cell carcinoma represents a rare but critical mechanism of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). This phenomenon poses significant challenges in patient management and treatment strategy.
- Understanding the molecular underpinnings and diagnostic methods for this transformation is crucial for improving outcomes in patients with EGFR-mutant lung adenocarcinoma.
Purpose of the Study:
- To investigate the utility of integrated cytological and molecular analysis of pleural fluid for diagnosing small cell carcinoma transformation in a patient with EGFR-mutant lung adenocarcinoma.
- To confirm the clonal origin of the transformed tumor and its relationship to the primary lung adenocarcinoma.
Main Methods:
- A case study of a 65-year-old woman with EGFR-mutant lung adenocarcinoma who developed pleural effusion after EGFR-TKI treatment.
- Analysis of pleural fluid cytology and cell block immunohistochemistry for small cell carcinoma markers (CD56, Syn, TTF-1).
- Molecular testing, including EGFR mutation analysis and single-cell sequencing, to assess the original mutation and clonal evolution.
Main Results:
- Pleural fluid cytology revealed features suggestive of small cell carcinoma, confirmed by immunohistochemistry.
- Molecular testing confirmed the persistence of the original EGFR exon 19 deletion mutation in the transformed tumor.
- Single-cell sequencing supported a clonal origin for both the primary and transformed tumors, indicating transformation rather than a separate event.
Conclusions:
- Integrated cytological and molecular analysis of pleural fluid is a powerful and minimally invasive approach to diagnose small cell transformation in EGFR-mutant lung adenocarcinoma.
- The shared EGFR mutation provides evidence of clonal evolution, highlighting transformation as the mechanism of acquired resistance.
- This diagnostic strategy offers a practical alternative to tissue re-biopsy for monitoring treatment resistance in lung cancer.